To The Moon

1. Institutional Positioning

Current Holdings: Major institutional holders include Vanguard (9.78%) , BlackRock (8.36%) , and Shah Capital (6.93%) , but there is no recent change in their positions (per latest filings).

Short Interest: Elevated short volume (e.g., 21.04% on April 2, 2025) suggests ongoing skepticism. However, the April 4, 2025 rally (+11.43%) coincided with a short-volume drop to 12.66%, hinting at possible short covering.

Capital Flows: Mixed signals – net inflows on April 1 (+993.5K) and April 4 (+1.81M) but outflows on April 3 (-2.02M). No clear evidence of sustained institutional accumulation.

2. Technical Resistance Levels

Immediate Resistance: $8.09 (April 4, 2025 high). This level previously capped rallies in March 2025.

Next Key Resistance: $9.00–$9.50 (January 2025 consolidation zone). A break above $8.09 could target this area, but the stock faces overhead supply from the Q1 2025 selloff.

Critical Long-Term Resistance : $10.82 (January 7, 2025 peak).

3. Price Context

Current Price: $6.48 (April 8, 2025), up 3.85% intraday.

Support: $5.71 (April 4, 2025 low).

Trend: The stock remains in a downtrend from its October 2024 high of $13.61, but the recent bounce off $5.71 suggests tentative bullish momentum.

4. Analyst Sentiment

Mixed Views: Analysts cite a mean target price of $17.67 (range: $9–$25), but the stock trades far below this.

Options Activity: Elevated implied volatility (per prior analysis) reflects high risk/reward speculation.

Disclaimer: This analysis is based on historical data and real-time metrics as of April 8, 2025. Market conditions can change rapidly. Novavax carries significant volatility due to its clinical-stage biotech profile. Always conduct independent research or consult a financial advisor before trading.